Pooled analysis demonstrated that SGLT2 inhibitors significantly reduced the composite of cardiovascular (CV) death or heart failure hospitalization (HHF) compared with placebo (HR 0.83; 95% CI 0.76–0.90;p < 0.0001) (Fig. 1). The gene discussed is SLC5A2; the disease is heart failure.